clinical trial · NCT04039607
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb·phase3·active not recruiting·n = 732
Hepatocellular CarcinomaNivolumabIpilimumabSorafeniblenvatinib
brief summary
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
started
Sep 30, 2019
primary completion
Jul 9, 2026
completion
Jul 9, 2026
last updated
Apr 6, 2026
official title
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol